BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 12.02.2020

Patient-Focused Drug Development for Vitiligo; Public Meeting; Request for Comments

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Patient-Focused Drug Development for Vitiligo." The purpose of the public meeting is to allow FDA to obtain patient perspectives on the impact of vitiligo on daily life, patient views on treatment approaches, and decision factors considered when selecting a treatment.

Source: Federal Register — Food and Drug AdministrationOpen original release →